Meeting highlights from the EMA Committee for Medicinal Products for Human Use (CHMP) (European Medicines Agency, 20 December 2013)

07 Jan 2014

Highlights of the December meeting of the European Medicines Agency Committee for Medicinal Products for Human Use include the granting of a conditional marketing authorisation for Cometriq (cabozantinib) for the treatment of medullary thyroid carcinoma, and the outcome of a safety review of topical use estradiols.